Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Karyopharm Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current filings are being reviewed across different technical groups within the USPTO, which may require distinct prosecution strategies for each application. The use of 2 distinct art units for only 2 actions suggests that the company's biotechnology filings are technically diverse.
RODRIGUEZ-GARCIA, VALERIE is the busiest examiner, responsible for 1 pending office action. This 1 action is among the 2 total pending office actions for the portfolio. The presence of 2 examiners across 2 art units means that the company must manage 2 separate examination timelines and sets of examiner preferences simultaneously. For the practitioner, this distribution indicates that the company's active patent strategy is not concentrated in a single technical niche, but is instead spread across multiple specialized groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18526900 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| 17368346 | IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY | GEORGE, DENNIS CHERIAN | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18526900 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103Other | Non-Final OA | — | Pending | Dec 01, 2023 |
| 17368346 | IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY | GEORGE, DENNIS CHERIAN | 1644 | §112 | Non-Final OA | — | Pending | Jul 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKaryopharm Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Karyopharm Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
